YOKENAM, Israel, Sept. 16, 2016 -- Lumenis Ltd., the world’s largest energy-based medical device company for surgical, aesthetic and ophthalmic applications, announces the introduction of OtoLase™, the new otology designated enhancement for the AcuPulse™ family of products. Specifically designed for enhanced precision and ease of use in middle ear surgery, the innovative OtoLase will be showcased at the American Academy of Otolaryngology – Head and Neck Surgery Foundation (AAO-HNSF) Annual meeting 2016, being held in San Diego on September 18-21, 2016.
|
||||||||||
Photos accompanying this release are available at http://www.globenewswire.com/NewsRoom/AttachmentNg/beee4af5-1eff-4d63-9b66-d01e88977f71 and http://www.globenewswire.com/NewsRoom/AttachmentNg/47010816-251b-4988-9289-b180a74dc97d.
The OtoLase solution, compatible with the AcuPulse DUO laser system, is a combination of reusable fiber and handpieces with different single-use tips, allowing for smooth, individualized and cost effective operation of varied pathologies in the middle ear. Based on clinical studies, otologic procedures with CO2 laser technology have shown superior outcomes compared with other modalities.1,2,3 With the ergonomic and operational design of OtoLase, surgeons are equipped with great precision and excellent visualization allowing them to remove layer-by-layer undesired tissue and enhance clinical outcomes of delicate ear procedures.
“OtoLase has been engineered for safety and ease of use. The air flow system eliminates the laser plume and facilitates visualization, and the aiming beam ensures target accuracy,” said John T. McElveen Jr., M.D. from Carolina Ear & Hearing Clinic in Raleigh, North Carolina. “The low profile and thin design allows the surgeon to reach the smallest recesses within the middle ear. This enhanced fiberoptic CO2 laser technology has been worth the wait.”
The versatile AcuPulse DUO laser system with OtoLase and the wide range of designated accessories, is an upgradable, all-inclusive solution for a range of diverse ear surgery treatments, including otosclerosis, cholesteatoma, tympanoplasty, myringotomy/tympanostomy, scar tissue dissection, acoustic neuroma and more. The laser system can be used for office and hospital-based procedures.
“With a 50-year history of redefining medical treatments and providing gold standard clinical advances, Lumenis has revolutionized the approach to micro laser surgery with its energy-based technology,” said Tzipi Ozer-Armon, CEO of Lumenis. “By striving to provide innovative tools to improve surgical performance, Lumenis continues to deliver next-generation energy-based solutions for our partners in the medical community and enhance patient care.”
AAO-HNSF conference attendees are invited to Lumenis booth #1635 to hear experts talk about their experience with the new OtoLase solution:
September 18-19 at 9:30 AM PT: Dr. Seilesh C. Babu
September 18-20 at 10 AM PT: Dr. John T. McElveen
In addition, Dr. Paul F. Castellanos will present his operating experience with the UltraPulse® DUO – the most advanced laser console in otolaryngology. His talk "The UltraPulse DUO CO2 Laser Fiber and the Difficult Airway" will take place on September 18 at 10:30 AM PT and September 19 at 1:30 PM PT.
Personal hands-on sessions on the Lumenis DUO platforms will be available all through the exhibiting hours at Lumenis booth. For more information about Lumenis, please visit: www.Lumenis.com.
About Lumenis
Lumenis is a global leader in the field of minimally-invasive clinical solutions for the Surgical, Ophthalmology and Aesthetic markets, and is a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL), Radio-Frequency (RF) and ultrasound. For nearly 50 years, Lumenis' ground-breaking products have redefined medical treatments and have set numerous technological and clinical gold-standards. Lumenis has successfully created solutions for previously untreatable conditions, as well as designed advanced technologies that have revolutionized existing treatment methods. For more information visit: www.lumenis.com
References:
1. Marchese, M.R., et al., "One-shot" CO2 versus Er:YAG laser stapedotomy: is the outcome the same? Eur Arch Otorhinolaryngol, 2011. 268(3): p. 351-6.
2. Lesinski SG, Lasers for otosclerosis--which one if any and why, Lasers Surg Med. 1990;10(5):448-57.
3. Motta, G. and L. Moscillo, Functional results in stapedotomy with and without CO2 laser. ORL J Otorhinolaryngol Relat Spec, 2002. 64(5): p. 307-10.
For further information: Glenn Silver Lazar Partners Ltd. (646) 871-8495


Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
Apple Turns 50: From Garage Startup to AI Crossroads
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 



